NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative return on equity of 34.20% and a negative net margin of 70,510.81%. View Endocyte's Earnings History.

4 analysts have issued twelve-month target prices for Endocyte's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Endocyte's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

Some companies that are related to Endocyte include Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA) and Clovis Oncology (CLVS).

News stories about ECYT stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a media sentiment score of 0.03 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Endocyte's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (8.19%), VHCP Management II LLC (6.19%), BlackRock Inc. (2.48%), Rock Springs Capital Management LP (0.97%), Eventide Asset Management LLC (0.50%) and Millennium Management LLC (0.27%). Company insiders that own Endocyte stock include Christopher P Leamon and Philip S Low. View Institutional Ownership Trends for Endocyte.

ECYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold Endocyte company stock in the last year include Christopher P Leamon and Philip S Low. View Insider Buying and Selling for Endocyte.

ECYT stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, VHCP Management II LLC, Rock Springs Capital Management LP, BlackRock Inc., Eventide Asset Management LLC, Tibra Equities Europe Ltd, Baird Financial Group Inc. and Element Capital Management LLC. View Insider Buying and Selling for Endocyte.

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ECYT stock can currently be purchased for approximately $14.52.

Endocyte has a market capitalization of $998.04 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.